COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort Study

OBJECTIVE: Patients with immune-mediated diseases treated with CD20 inhibitors may have worse COVID-19 outcomes due to impaired humoral immunity, but differences versus the general population are unknown. METHODS: We identified patients with immune-mediated diseases who received CD20 inhibitors with...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Naomi J., D’Silva, Kristin M., Hsu, Tiffany Y-T., DiIorio, Michael, Fu, Xiaoqing, Cook, Claire, Prisco, Lauren, Martin, Lily, Vanni, Kathleen M.M., Zaccardelli, Alessandra, Zhang, Yuqing, Sparks, Jeffrey A., Wallace, Zachary S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366799/
https://www.ncbi.nlm.nih.gov/pubmed/34401883
http://dx.doi.org/10.1101/2021.08.05.21261643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366799/
https://www.ncbi.nlm.nih.gov/pubmed/34401883
http://dx.doi.org/10.1101/2021.08.05.21261643

Ejemplares similares